Oral rifaximin for active microscopic colitis flare
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have microscopic colitis confirmed by colon biopsy showing collagenous colitis or lymphocytic colitis
- Your diagnosis must have been reviewed and confirmed by two separate pathology experts
- You are currently in an active flare with more than 3 watery or loose stools per day
- Your flare has lasted enough time (at least 4 days out of the last 7, during the past 4 weeks)
- Your symptoms happened within the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication (SAR444336) can help adults with microscopic colitis stay in remission longer. It may be an option if you are already taking budesonide and have had flares in the past 8 months.
This Phase 2 trial compares two forms of the same medicine, budesonide, to see which one works better and is safer for bringing microscopic colitis symptoms under control. If you have active watery/loose diarrhea and confirmed microscopic colitis, you may be offered one of these treatments to induce remission.
This trial tests whether the antibiotic rifaximin can prevent pouchitis from coming back after a first episode. It is for people who had ulcerative colitis, have a J-pouch, and developed pouchitis within the first year after their final surgery.
This trial tests if adding the gut antibiotic rifaximin to ticagrelor (a blood thinner) can further reduce the risk of blood clots in people who've had a heart attack. It's for patients whose platelets are still too active despite taking ticagrelor.
This study tests whether rifaximin, an antibiotic that works in the gut, can reduce bloating in people with irritable bowel syndrome, constipation, or functional bloating. Rifaximin may help by changing the balance of bacteria in your intestines.
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Hear when a new Microscopic Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.